Substance Use and Mental Health Outcomes for Comorbid Patients in Psychiatric Day Treatment

Stephen Magura¹, Andrew Rosenblum² and Thomas Betzler³

¹The Evaluation Center, Western Michigan University, Kalamazoo, MI. ²National Development and Research Institutes, New York, NY. ³Albert Einstein College of Medicine, New York, NY. Email: stephen.magura@wmich.edu

Abstract: The study’s purpose was to determine treatment outcomes for patients who present with drug use vs. those presenting with no drug use at admission to a psychiatric day treatment program. Consecutively admitted patients completed confidential interviews which included psychological distress and quality of life measures and provided urine specimens for toxicology at admission and six month follow-up. Subjects positive by past 30 day self-report or urinalysis were categorized as drug users. Major psychiatric diagnoses were: major depression 25%; bipolar, 13%; other mood 13%; schizoaffective 13%; schizophrenia 13%. Drug use at admission was: cocaine 35%; marijuana 33%; opiates 18%, (meth)amphetamines, 6% For each of these drugs, the percentage of patients positive at admission who remitted from using the drug significantly exceeded the percentage negative at baseline who initiated using the drug. Overall, there were significant decreases in psychological distress and significant improvement on quality of life, but no change on positive affect. There were no significant differences between drug users and non-drug users on symptom reduction and improvement in quality of life. Psychiatric day treatment appears to benefit comorbid patients by reducing the net number of patients who actively use certain common drugs and by improving psychological status and quality of life to the same degree as for non-drug using patients.

Keywords: substance abuse, psychiatric treatment, treatment outcomes, comorbidity, co-occurring disorders
**Introduction**

In 2007, according to the National Survey of Drug Use and Health (NSDUH), there were an estimated 24.3 million adults aged 18 or older in the United States with Serious Psychological Distress (SPD) in the past year. This represents 10.9 percent of all adults in the USA. Meeting the criteria for SPD indicates that the respondent endorsed having symptoms at a level known to be indicative of having a mental disorder (i.e. any disorder such as an anxiety or mood disorder). SPD in the past year was associated with past year substance dependence or abuse. Among adults with SPD, 22.1 percent were dependent on or abused illicit drugs or alcohol. The rate of illicit drug dependence or abuse among adults without SPD was 7.6 percent. The U.S. National Comorbidity Survey Replication, conducted during 2001–2003, found that past 12-month substance disorders were significantly correlated with a variety of psychiatric disorders, primarily major depressive disorder, social phobia, generalized anxiety disorder, manic/hypomanic disorder, attention-deficit/hyperactivity disorder, dysthymia and intermittent explosive disorder.

Comorbid disorders are more severe and chronic than single psychiatric disorders. In the general population, persons with lifetime comorbidity are more likely than those with only one disorder to experience major impairments with economic domains (e.g. unemployment, financial problems), social isolation, and interpersonal conflicts. Comorbidity is highly predictive of negative treatment outcomes. Among substance abuse patients, the severity of psychiatric symptoms is associated with poorer outcomes. Among mental health patients, particularly persons with schizophrenia, a comorbid addictive disorder has been associated with mental health treatment and medication, higher re-hospitalization and emergency room visits, homelessness, criminality and violence, suicide attempts, increased fluctuation and severity of psychiatric symptoms, legal problems, family stress, and HIV/HCV infection.

**Purpose of the Study**

The study’s purpose is to determine treatment outcomes for patients who present with drug use vs. those presenting with no drug use at admission to a psychiatric day treatment program with dual diagnosis capability. The analysis extends previous research on drug use comorbidity in psychiatric treatment in several ways:

- Drug use was measured by confidential research interviews and urinalysis at treatment admission and follow-up.
- Drug use and psychiatric symptoms were measured using the same procedures at admission and follow-up.
- An unselected psychiatric diagnostic sample was studied (i.e. not limited to one diagnosis such as schizophrenia or major depression).
- Outcomes were compared for psychiatric-only versus comorbid drug-using patients in psychiatric day treatment, in contrast to previous research conducted either with inpatients or with a comorbid sample only.

**Methods**

**Setting**

The setting was a psychiatric continuing day treatment program located in New York City. Patients in this program usually have a three times a week, half-day schedule, either in the morning or afternoon, and participate in one to four groups per day. Patients are offered breakfast and lunch on days they come to the program. The program provides mental health services for persons with single psychiatric disorders as well as for those dually diagnosed with psychiatric and substance use disorders. Specialized groups are offered for patients with co-occurring disorders, such as “Substance Abuse Awareness” “Relapse Prevention,” and a 12 Step-based dual recovery group. The program falls into the category of dual diagnosis-capable mental health treatment (but not integrated treatment).

**Study sample**

Two cohorts of patients newly admitted to the program were recruited as part of a larger research study, the first from March to December 2003 (n = 81) and the second from May 2004 to December 2005 (n = 148), for a total of 229 patients. Patients were referred from various mental health and drug treatment settings, including psychiatric inpatient units, mental health residences, other outpatient mental health clinics,
outpatient drug abuse treatment clinics, or were self-referred through community contacts.

**Study procedures**
Consecutive admissions to the program were referred by a program intake counselor to a study research assistant. Patients were excluded from study participation only if they were younger than age 18, did not understand or speak English, appeared intoxicated on drugs or alcohol, carried a diagnosis of mental retardation, were deemed actively psychotic by the clinic’s intake coordinator, or appeared unable to understand and give informed consent.

All patients who agreed to participate in the study signed an informed consent. Participants received compensation of $20 for a confidential baseline interview and biological specimens and $40 for the similar follow-up protocol six months after admission. Follow-up was attempted for all subjects even if they had left the program. The response rate at follow-up was 82%.

The study protocol was approved by the Institutional Review Boards (IRBs) of the host research site and the organization that conducted the study.

**Study measures**

**Substance use self-reports**
The Drug/Alcohol Use section of the Addiction Severity Index (ASI) includes a list of drugs asking the number of days in the past 30 that each drug was used.

**Drug toxicology**
Urine specimens were obtained and toxicology was conducted by on-site immunoassay (Roche TestCup) for opiates (morphine), cocaine metabolite (benzoylcegonine), marijuana (THC), and amphetamines. Urine specimens were obtained for 96.8% of the sample.

**Colorado symptom index (CSI)**
The CSI was developed specifically for assessment of symptoms at levels experienced by people diagnosed with mental illness; it has been independently validated.

**Symptom checklist-10R (SCL-10R)**
The SCL-10R was developed to broadly represent both primary and secondary factors of the SCL-90; items from each of the original nine subscales of the SCL-90 are included. The SCL-10R contains six primary factor items and four additional items to include secondary factors of somatization, phobic avoidance, hostility and paranoia. The SCL-10R was developed to provide a brief measure of psychological distress that can be used with heterogeneous clinical populations; it is highly correlated with the total score of the SCL-90.

**Positive affect (PA)**
This is the Positive Affect scale from the Positive and Negative Affect Schedule (PANAS); it was chosen as a measure of positive mood that differs from the negative symptom scales. The PANAS scales have satisfactory psychometrics and are widely used as a measure of mood states.

**Quality of life (QoL)**
This was measured by the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), developed for use with patients with mental and other medical conditions as well as non-patients, that has been independently validated. The Social Relationships and Leisure Time Activities subscales were combined into a single additive index.

All the above measures were obtained at treatment admission and follow-up and were used to assess treatment outcomes. These data were obtained confidentially for research purposes and were not shared with program staff.

**DSM-IV disorders**
At admission, program psychiatrists diagnosed past 12-month DSM-IV psychiatric and substance use disorders. We report these data descriptively, but meeting or not meeting DSM-IV criteria was not employed as an outcome measure because the program does not repeat these diagnoses, 12 month prevalence would not be usable for a six-month follow-up, and changes in psychiatric status and substance use in clinical research are typically measured by comparing symptomatology between restricted time periods (e.g. 30 day windows).

**Study definition of drug use comorbidity**
Patients are defined as comorbid if they reported any use of cocaine, opiates (illicit or illicitly obtained), marijuana, or (meth)amphetamine in the 30 days prior to admission or if they tested urine-positive for one of
these four classes of drugs at admission. Twelve-month DSM-IV diagnosis of drug dependence or abuse at admission was not employed to define comorbidity because such patients would not necessarily be using drugs prior to admission and moreover, there is internal evidence that many patients who are using drugs extensively (or did so within the last year) are not diagnosed because of their reluctance to disclose use to program staff at admission.30

Substance use history
A patient was classified as having a lifetime substance use history if any of the following obtained: Prior drug/alcohol treatment or detoxification episode(s); prior participation in 12 step groups for drugs/alcohol; past regular use of specific drugs or alcohol (defined as weekly or more frequent use over at least one year); meeting lifetime criteria for drug or alcohol use disorder on the M.I.N.I.31

Statistical analysis
Outcomes are analyzed with contingency tables, difference of means, ordinary least squares multiple regression and multiple logistic regression. Statistical significance is set at \( p < 0.05 \) (2-tailed). The outcome analyses are based on the follow-up sample of \( N = 187 \). Changes in the use of specific drugs between admission and follow-up are presented for cocaine, opiates, marijuana and amphetamines because for these drugs the study has both self-reports and urinalysis, the latter enhancing the validity of the measures.

Results
Characteristics of sample
The majority (60%) of the sample was male and from minority groups, with an average age of 39 years. Most were supported by public assistance (69%), had substance use histories (93%) and had prior episodes of psychiatric treatment (90%) (Table 1).

At admission to this program, the most frequent primary psychiatric diagnosis was major depression (25%), followed by equal frequencies of bipolar (13%), other mood (13%), schizoaffective (13%) and schizophrenic (13%) disorders (Table 2).

The most frequent drugs used within 30 days before admission (based on both self-reports and urinalysis) were cocaine/crack (33%), marijuana (33%), opiates (18%), and amphetamines (6%); 61%

had used at least one of these four drugs (Table 3). The amount of use among patients who reported use was substantial; the mean days used in the past 30 was 11.4 for cocaine/crack, 11.2 for marijuana and 9.6 for opiates. However, there was no self-reported use of (meth)amphetamines; all (meth)amphetamine users were classified as such by positive urinalysis. We examined how many patients were classified as drug users based solely on what could be characterized as infrequent recreational use of marijuana, which we defined as one or two days of use in the past 30; this was only 10 patients or 4.4% (10/229) of the sample.

| Table 1. Sample characteristics at admission to treatment (n = 229). |
|-------------------------------|---------|
| Male                          | 60%     |
| Hispanic                      | 41%     |
| Black                         | 42%     |
| White                         | 18%     |
| Currently employed            | 3%      |
| Public assistance              | 69%     |
| Unstable housing               | 16%     |
| Substance use history         | 93%     |
| Ever received psychiatric treatment | 90%   |
| Age in years (mean, sd)        | 39 (9.1)|

| Table 2. DSM-IV Axis I diagnoses – 12 month (n = 229). |
|-------------------------------|---------|
| Major depression              | 25%     |
| Bipolar                       | 13%     |
| Other mood disorders           | 13%     |
| Schizoaffective                | 13%     |
| Schizophrenia                 | 13%     |
| Psychotic disorders NOS       | 7%      |
| Anxiety disorders              | 3%      |
| Other disorders                | 13%     |
| Cocaine                       | 11%     |
| Opioids                       | 11%     |
| Marijuana                      | 8%      |
| Sedatives                     | 4%      |
| Polysubstance                  | 11%     |
| Any drug                       | 34%     |
| Alcohol                       | 11%     |

Note: Substance use diagnoses represent one of up to three disorders recorded by program psychiatrists; other diagnoses represent the primary diagnosis.
Drug use outcomes
For each individual drug, the percentage of patients positive at admission who remitted from drug use at six months after admission significantly exceeded the percentage negative at baseline who initiated drug use. These respective percents were 48% vs. 11% for cocaine, 35% vs. 17% for marijuana, 58% vs. 9% for opiates and 100% vs. 2% for amphetamines (Table 4). However, overall use of any of the four drugs decreased only slightly, from 59% of subjects at admission to 51% of subjects at follow-up (based on the follow-up sample of 187).

Mental health outcomes
Overall in the sample, there were significant decreases in symptoms on the Colorado Symptoms Index and the Symptom Checklist-10R and significant improvement on Quality of Life, with no change on Positive Affect (Table 5).

Further, based on regression analyses, there were no significant differences between those identified at admission as drug users vs. non-drug users in psychological symptom reduction or in improvement on Quality of Life, controlling for the baseline value of each outcome (Table 6).

It is possible that alcohol misuse at admission might suppress a relationship between drug use and psychiatric outcomes. We constructed a variable, “alcohol intoxication days at admission,” ranging from 0–30, and entered it as a covariate in the regressions in table 6; this variable was not significant and did not alter the lack of association between substance use and clinical outcomes.

Discussion and Conclusions
Surprisingly, there are almost no previous studies comparing psychiatric and/or drug use outcomes for psychiatric-only versus comorbid drug-using adult patients in either standard or “dual diagnosis-capable” psychiatric day treatment. Virtually all previous

| Table 3. Drug use at admission—positive self-report or urinalysis (n = 229). |
|-----------------------------------------------|
| Drug of choice | Percentage |
| Cocaine | 35% |
| Marijuana | 33% |
| Opiates | 18% |
| (Meth)amphetamines | 6% |
| Any of these 4 drugs | 61% |

| Table 4. Changes in drug use (N = 187). |
|-----------------------------------------------|
| Drug of choice | Positive at admission who remitted at follow-up [%] | Negative at admission who initiated by follow-up [%] | P-value |
| Cocaine | 48% (30/62) | 11% (14/125) | <0.001 |
| Marijuana | 35% (20/58) | 17% (22/129) | <0.01 |
| Opiates | 58% (21/36) | 9% (14/151) | <0.000 |
| (Meth)amphetamines | 100% (11/11) | 2% (4/176) | <0.000 |

| Table 5. Changes in mental health (N = 187). |
|-----------------------------------------------|
| Outcome (dependent) | Admission M (SD) | Follow-up M (SD) | P-value |
|----------------------|------------------|------------------|----------|
| Colorado symptoms index | 2.64 (1.10) | 2.31 (0.97) | <0.000 |
| Symptom Checklist-10 | 1.75 (1.05) | 1.46 (0.99) | <0.000 |
| Positive affect | 2.99 (1.10) | 2.99 (0.98) | NS |
| Quality of life | 3.32 (0.69) | 3.43 (0.69) | <0.05 |

| Table 6. Effect of drug use at admission on mental health outcomes. |
|-----------------------------------------------|
| Outcome (dependent): Colorado symptoms index (CSI) |
| Predictors | B | SE B | T | P-value |
| Drug use at admission | 0.044 | 0.119 | 0.37 | 0.71 (NS) |
| CSI at admission | 0.556 | 0.058 | 9.57 | <0.000 |
| Outcome (dependent): Symptom checklist -10 (SCL) |
| Drug use at admission | -0.041 | 0.116 | -0.35 | 0.73 (NS) |
| SCL at admission | 0.589 | 0.055 | 10.81 | <0.000 |
| Outcome (dependent): Quality of Life (QoL) |
| Drug use at admission | -0.081 | 0.094 | -0.86 | 0.39 (NS) |
| QoL at admission | 0.417 | 0.067 | 6.25 | <0.000 |
studies have been in primary addiction programs, or in inpatient settings, or have evaluated outcomes of integrated and other psychiatric treatments for comorbid patients only, without single disorder comparison groups.

There is value in better understanding outcomes for comorbid patients in dual diagnosis-capable psychiatric programs. Simultaneous treatment for substance use disorders and serious mental illness is still infrequent; data based on the National Survey of Drug Use and Health indicates that only 15.5% of persons with both disorders receive both forms of treatment. No numeric estimate is available of what proportion of that is fully integrated treatment, but fully integrated treatment is believed to remain rare and perhaps even decreasing due to resource constraints. Thus, dual diagnosis-capable treatment is presently a more realistic service option; this study shows that patients presenting with drug use can benefit psychiatrically from such treatment to about the same degree as patients presenting without drug use.

There are only a few previous studies to which our results can plausibly be compared, although there remain many differences among the studies. A 12-month prospective follow-up was conducted of schizophrenic patients with and without a substance disorder receiving continuing mental health care, concluding that the “dual disorder patients in this cohort did no worse than the single disorder patients with respect to positive and negative psychiatric symptoms” and that the treatment “did not significantly impact levels of alcohol and drug use”. Outcomes at 8 weeks after admission to a “standard” psychiatric day treatment program were compared for patients with and without “coexisting alcohol and/or drug abuse;” the substance abusers left treatment at higher rates and had more suspensions, including for continuing abuse.

Chouljian et al compared substance use outcomes over 18 months for schizophrenic outpatients with and without “problem substance use;” the overall level of substance use and problem use remained stable, while problem use of cocaine and polysubstance use increased over time. A clinical trial of citalopram for outpatients with major depression compared outcomes among several diagnostic subgroups including patients with comorbid substance use disorder only and those with no comorbid anxiety or substance use disorders; these two groups did not differ significantly on changes in depressive symptom severity. Changes in substance use were not reported. The results of these studies for psychiatric symptom change are similar to the current study, although the current study cannot examine outcomes for specific psychiatric diagnostic groups, since the sample sizes of those groups are too small. None of the programs in which the above studies were conducted appear to have been dual diagnosis-capable, which may account for the lack of influence on substance use, whereas the current study did identify a limited positive effect, at least in terms of remission.

Ours may also be the first study to report the rate of initiation of several major types of drug use among psychiatric outpatients who were abstinent from those drugs at treatment admission. Confidence in the results is increased because drug tests were included in the drug use measure, in contrast to virtually all previous outcome research in psychiatric day treatment. Underreporting of drug use in high risk populations is a pervasive problem in research.

Psychiatric day treatment appears to benefit comorbid patients through substantial remission rates from cocaine, marijuana, opiate and amphetamine use by six months after admission. Yet overall drug use decreased only slightly because some patients who were abstinent at admission, initiated use of one of the index drugs by follow-up. Virtually all the patients reported substance use histories (93%) and it may be that some or all of the remaining 7% failed to disclose or forgot; thus, this sample was highly susceptible to relapse. Although relapse rates were not high for any individual drug (Table 4), because a large majority was not using any given drug at baseline, even low relapse rates led to considerable absolute numbers of relapers.

Preventing relapse to drug use is a challenge for psychiatric day treatment, because virtually all patients may be at risk, and it is difficult to predict who actually will relapse. However, clinical attention to the risk of relapse would be facilitated if day treatment programs broadened or improved assessment procedures for determining drug use at admission. A previous paper showed that this program using typical clinical interviews identified only a fraction
of the patients with drug use at admission; drug toxicologies should be considered as part of a comprehensive assessment at admission.

Psychiatric day treatment was associated with significant improvements in psychological distress and quality of life for the sample as a whole, although one measure, positive affect, did not show change. The most encouraging finding was that there were no significant differences in mental health improvements between patients who used one of four common illicit drugs at admission vs. patients who were abstinent from these drugs at admission. Although the present program was not an integrated treatment model, it was dual diagnosis-capable, e.g. providing specialized group therapy and peer support groups that address comorbidity issues, which may help account for these encouraging results.

Funded
NIDA grant R01DA015912.

Disclosures
The authors report no conflicts of interest.

References
1. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Results from the 2007 National Survey on Drug Use and Health: National Findings (NSDUH Series H-34, DHHS Publication No. SMA 08-4343). Rockville, MD, 2008.
2. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617–27.
3. Hagnell O, Grasbeck, A. Comorbidity of anxiety and depression in the Lunby 25-year prospective study: The pattern of subsequent episodes. In: Comorbidity of Mood and Anxiety Disorders. Maser JD, Cloninger CR, eds. Washington, DC: American Psychiatric Press; 1990:139–52.
4. Hirschfeld RMA, Hasin D, Keller MB, Endicott J, Wunder J. Depression and alcoholism: Comorbidity in a longitudinal study. In: Comorbidity of Mood and Anxiety Disorders. Maser JD, Cloninger CR, eds. Washington, DC: American Psychiatric Press; 1990:293–304.
5. Kessler RC. The national comorbidity survey: preliminary results and future directions. International Journal of Methods in Psychiatric Research. 1995;5:139–51.
6. Murphy JM. Diagnostic comorbidity and symptom co-occurrence: the Stirling County Study. In: Comorbidity of Mood and Anxiety Disorders. Maser JD, Cloninger CR, eds. Washington, DC: American Psychiatric Press; 1990:153–76.
7. Gonzalez G, Rosenheck R. Outcome and service use among homeless persons with serious mental illness and substance abuse. Psychiatric Services. 2002;53(4):437–46.
8. Donat DC, Haverkamp J. Treatment of psychiatric impairment complicated by co-occurring substance use: impact of rel Hepatology. Psych Rehab J. 2004;28 (1):78–82.
9. McLellan AT, Luborsky L, Woody GE, O’Brien CP, Druley, K. Predicting response to alcohol and drug abuse treatments: Role of psychiatric severity. Arch Gen Psychiatry. 1983;40:620–25.
10. Rounsaville BJ, Kosten TR, Weissman MM, Kleber D. Prognostic significance of psychopathology in treated opiate addicts. Arch Gen Psychiatry. 1986;43:739–45.
11. Walker RD, Donovan DM, Kiivaha, DR, O’Leary MR. Length of stay, neuropsychological performance, and aftercare: Influences on alcohol treatment outcome. J Consult Clin Psychol. 1983;51:900–11.
12. Bartels SJ, Teague GB, Drake RE, Clark RE, Bush PW, Noordsy DL. Substance abuse in schizophrenia: Service utilization and costs. J Nerv Ment Dis. 1993;181:227–32.
13. Bergman HC, Harris M. Substance abuse among young adult chronic patients. Psychosocial Rehabilitation Journal. 1985;9:49–54.
14. Buckley PF, Brown ES. Prevalence and consequences of dual diagnosis. J Clin Psychiatry. 2006;67(7):e01.
15. Compton MT, Weiss PS, West JC, Kasl NJ. The associations between substance use disorders, schizophrenia-spectrum disorders, and Axis IV psychosocial problems. Soc Psychiatry Psychiatr Epidemiol. 2005;40(12):939–46.
16. Drake RE, Brunette MF. Complications of severe mental illness related to alcohol and drug use disorders. In: Galanter M. (Ed.) Recent Developments in Alcoholism, Vol. 14: The Consequences of Alcohol (p. 285–99). New York: Plenum; 1998.
17. Mueser KT, Bellack AS, Blanchard JD. Comorbidity of schizophrenia and substance abuse: Implications for treatment. J Consult Clin Psychol. 1992;60:845–56.
18. Osher FC, Kofoed LL. Treatment of patients with psychiatric and psychoactive substance use disorders. Hospital and Community Psychiatry. 1989;40(10):1025–30.
19. Osher FC, Drake RE, Noordsy DL. Correlates and outcomes of alcohol use disorder among rural outpatients with schizophrenia. J Clin Psychiatry. 1994;55:109–13.
20. Westermeyer J, Walzer V. Sociopathology and drug abuse in a young psychiatric population. Diseases of the Nervous System. 1985;36:673–77.
21. Rosenberg SD, Drake RE, Brunette MF, Worford GL, Marsh BJ. Hepatitis C virus and HIV co-infection in people with severe mental illness and substance use disorders. AIDS. 2005;19(3):S26–33.
22. Gotham JJ, Brown JL, Comaty JE, McGovern MP. Dual Diagnosis Capability in Mental Health Treatment (DDCMHT) Version 3.2. http://dms.dartmouth.edu/re/cd/dual/pdf/ddcmht_index.pdf. Accessed Sept 9, 2009.
23. McLellan AT, Kushner H, Metzger D, et al. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9(3):199–213.
24. Shern DL, Wilson NZ, Coen AS, et al. Client outcomes II: longitudinal client data from the Colorado treatment outcome study. The Milbank Quarterly. 1994;72(1):123–48.
25. Boothroyd RA, Chen HJ. The psychometric properties of the Colorado Symptom Index. Adv Policy Ment Health. 2008;35(5):370–8.
26. Rosen C, Dreschler K, Moos R, Finney J, Murphy R, Gusman F. Six and ten Item indices of psychological distress based on the Symptom Checklist-90. Assessment. 2000;7:103–11.
27. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: The PANAS scales. Journal of Personality and Social Psychology. 1988;54(6):1063–70.
28. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacological Bulletin. 1993;29(2):321–6.
29. Bishop SL, Walling DF, Dott SG, Folkes CC, Bucy J. Defining quality of life: Validating a multidimensional factor measure in the severe mentally ill. Quality of Life Research. 1999;8(1–2):151–60.
30. Magura S, Spybrook J, Rosenblum A, et al. Undiagnosed drug use among admissions to psychiatric day treatment and prediction of early exit. (In submission).
31. Sheehan DV, Lecrubier Y, Harnett-Sheehan K, et al, The Mini International Neuropsychiatric Interview (M.I.N.I.): The Development and Validation of a Structured Diagnostic Psychiatric Interview. J Clin Psychiatry. 1998;59(Suppl 20):22–33.
32. Center for Substance Abuse Treatment. Substance abuse treatment for persons with co-occurring disorders. Treatment Improvement Protocol (TIP) Series 42. DHHS Publication no. (SMA) 05-3992. Rockville MD: Substance Abuse and Mental Health Services Administration, 2005.
33. Flynn PM, Brown BS. Co-occurring disorders in substance abuse treatment: Issues and prospects. *J Substance Abuse Treatment*. 2008; 34(1):36–47.

34. Dixon L, McNary S, Lehman AF. Remission of substance use disorder among psychiatric inpatients with mental illness. *Am J Psychiatry*. 1998; 155(2):239–43.

35. Caspari D. Cannabis and schizophrenia: results of a follow-up study. *Eur Arch Psychiatry Clin Neurosci*. 1999;249(1):45–9.

36. Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. *Schizophr Res*. 2002;54(3):253–64.

37. Sacks S, Banks S, McKendrick K, Sacks JY. Modified therapeutic community for co-occurring disorders: a summary of four studies. *J Subst Abuse Treat*. 2008;34(1):112–22.

38. Drake RE, O’Neal EL, Wallach MA. A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. *J Subst Abuse Treat*. 2008;34(1):123–38.

39. Harris KM, Edlund MJ. Use of mental health care and substance abuse treatment among adults with co-occurring disorders. *Psychiatr Serv*. 2005; 56(8):954–9.

40. Margolese HC, Negrete JC, Tempier R, Gill K. A 12-month prospective follow-up study of patients with schizophrenia-spectrum disorders and substance abuse: changes in psychiatric symptoms and substance use. *Schizophr Res*. 2006;83(1):65–75.

41. Case N. The dual-diagnosis patient in a psychiatric day treatment program: a treatment failure. *J Substance Abuse Treatment*. 1991;8(1–2):69–73.

42. Chouljian TL, Shumway M, Balancio E, Dwyer EV, Surber R, Jacobs M. Substance use among schizophrenic outpatients: prevalence, course, and relation to functional status. *Ann Clin Psychiatry*. 1995;7(1):19–24.

43. Howland RH, Rush AJ, Wisniewski SR, et al. Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. *Drug Alcohol Depend*. 2009; 99(1–3):248–60.

44. Magura S, Kang SY. Validity of self-reported drug use in high risk populations: a meta-analytical review. *Subst Use Misuse*. 1996;31(9):1131–53.

---

**Publish with Libertas Academica and every scientist working in your field can read your article**

“I would like to say that this is the most author-friendly editing process I have experienced in over 150 publications. Thank you most sincerely.”

“The communication between your staff and me has been terrific. Whenever progress is made with the manuscript, I receive notice. Quite honestly, I’ve never had such complete communication with a journal.”

“LA is different, and hopefully represents a kind of scientific publication machinery that removes the hurdles from free flow of scientific thought.”

**Your paper will be:**
- Available to your entire community free of charge
- Fairly and quickly peer reviewed
- Yours! You retain copyright

[http://www.la-press.com](http://www.la-press.com)